Conferences IDWeek 2016
Other Infections
IDWeek 2016: Comorbidities Are Common and Rising Among People with HIV
- Details
- Category: HIV-Related Conditions
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
People living with HIV are increasingly experiencing a range of non-AIDS-related comorbidities as the population ages, including cardiovascular disease, kidney impairment, and bone loss leading to fractures, according to research presented at the recent IDWeek 2016 meeting in New Orleans.
Young Adolescents Need Only 2 Doses of Human Papillomavirus Vaccine, CDC Says
- Details
- Category: HPV Vaccines
- Published on Tuesday, 08 November 2016 00:00
- Written by Liz Highleyman
Adolescents age 11-14 years can receive 2 doses of the human papillomavirus (HPV) vaccine to prevent cancers caused by HPV, rather than the 3 doses previously recommended, according to the U.S. Centers for Disease Control and Prevention (CDC). This change is supported by a systematic review presented at the recent IDWeek meeting in New Orleans, which found that 2 vaccine doses were non-inferior to 3 doses for this age group.
New Research Sheds Light on Origin of HIV in U.S., Dispelling Patient Zero Myth
- Details
- Category: HIV Prevention
- Published on Wednesday, 02 November 2016 00:00
- Written by Liz Highleyman
A new genetic analysis shows that HIV likely spread from the Caribbean to New York City around 1971 and from there to San Francisco around 1976, laying to rest the misconception that a Canadian flight attendant, Gaetan Dugas, was responsible for sparking the epidemic in the United States.
IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Liz Highleyman
A new 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week course cured 99% of treatment-experienced patients, researchers reported at the recent IDWeek meeting in New Orleans. Response rates dropped off, however, when treatment was shortened to 6 weeks.
IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women
- Details
- Category: Approved HIV Drugs
- Published on Monday, 31 October 2016 00:00
- Written by Liz Highleyman
A once-daily regimen containing the potent HIV integrase inhibitor dolutegravir worked better than an older atazanavir-containing regimen -- with higher rates of viral suppression both overall and across race subgroups -- in the ARIA trial, one of the few antiretroviral therapy studies to enroll only women, according to a presentation at IDWeek last week in New Orleans.
IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.
IDWeek 2016: Do HIV-Positive Men with Undetectable Viral Load Need to Wear Condoms?
- Details
- Category: HIV Prevention
- Published on Friday, 28 October 2016 00:00
- Written by Liz Highleyman
In the face of extensive research showing that HIV-positive people on antiretroviral therapy (ART) with stable undetectable viral load have an extremely low likelihood of transmitting the virus, a majority of participants at IDWeek 2016 in New Orleans thought they should still be advised to use condoms -- a proportion that actually increased after a debate that laid out the evidence.
IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
Long-term use of omega-3 fatty acid supplements was associated with reduced levels of triglycerides and the inflammation biomarker C-reactive protein (CRP) in HIV-positive people with suppressed viral load, according to research presented last week at IDWeek 2016 in New Orleans.
IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 28 October 2016 00:00
- Written by Liz Highleyman
Ibalizumab, an experimental antiretroviral agent that works differently than existing HIV drugs, demonstrated promising safety and antiviral activity in a small Phase 3 study of people with highly drug-resistant virus, according to a report at the IDWeek conference this week in New Orleans. If confirmed in larger studies, this could be good news for HIV patients who cannot be successfully treated using available therapies.
Web Design and Development by